Procter & Gamble Health Limited Secures Exchange Approval for Promoter Reclassification Aug 18, 2025
Procter & Gamble Health Reports Strong Q1 Performance with Net Profit Surging to 662M Rupees Aug 01, 2025
More news about Procter & Gamble Health
30Jul 25
P&G Hygiene Shares Surge as Quarterly Profit Doubles to ₹192 Crore
Procter & Gamble Health reported impressive Q2 results with net profit doubling to ₹192.00 crore from ₹81.00 crore year-over-year. Revenue marginally increased by 0.6% to ₹937.00 crore. EBITDA rose significantly to ₹266.00 crore, with EBITDA margin expanding to 28.4% from 12.7%. The stock price surged, reaching an intraday high of ₹14,540.00 (11.06% increase). Management attributed the strong performance to successful execution of their integrated growth strategy focusing on daily use categories and product superiority.
30May 25
Procter & Gamble Health Reports Q4 Profit Surge and Announces Dividend
Procter & Gamble Health's Q4 net profit rose 31.4% year-over-year to ₹612.00 million, while revenue increased 23% to ₹3.10 billion. However, net profit decreased 32.7% quarter-over-quarter. The company's board recommended a dividend of ₹45.00 per equity share.
Procter & Gamble Health announced impressive Q3 financial results. Net profit increased by 31.30% to ₹61.20 crore, while revenue grew by 23.20% to ₹311.00 crore. EBITDA rose by 20.20% to ₹81.00 crore. The company's board recommended a dividend of ₹45.00 per equity share. For the nine-month period, sales increased by 8.00% to ₹918.00 crore, and Profit After Tax grew by 27.00% to ₹234.00 crore.
28May 25
P&G India Misses Q3 Expectations, Long-Term Growth Remains Steady
Procter & Gamble Hygiene and Health Care Ltd (P&G India) reported disappointing Q3 results, falling short of market expectations. However, the company's long-term growth trajectory remains positive. P&G India has maintained a consistent revenue CAGR of 7.00% from FY19 to FY24, expected to continue through FY27E. Despite quarterly inconsistencies, annual performance shows steady growth. The company has improved its EBITDA margin by 250 basis points to approximately 23.50% over the FY19-FY24 period.